Recent Quotes (30 days)

You have no recent quotes
chg | %

Silence Therapeutics plc  

(Public, LON:SLN)   Watch this stock  
Find more results for SLN
-0.75 (-0.67%)
Aug 26 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 111.75 - 112.31
52 week 96.62 - 260.00
Open 112.00
Vol / Avg. 3,639.00/44,919.00
Mkt cap 77.66M*
P/E     -
Div/yield     -
EPS -0.11*
Shares 69.80M
Beta     -
Inst. own     -
Aug 10, 2016
Silence Therapeutics PLC at Canaccord Genuity Growth Conference
May 31, 2016
Silence Therapeutics PLC Annual Shareholders Meeting (Estimated)

Key stats and ratios

Q4 (Dec '15) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -8.02% -14.55%
Return on average equity -8.15% -15.07%
Employees 56 -
CDP Score - -


72 Hammersmith Road
United Kingdom - Map
+44-20-34576900 (Phone)
+44-7-957318494 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance


Silence Therapeutics plc is a United Kingdom-based drug development company. The Company is engaged in the development and delivery of ribonucleic acid (RNA) therapeutics. The Company's RNA technology harnesses the body's natural mechanisms to create therapeutic effects within its own cells. The Company's technology is in the clinic and has been used in Phase II trials. Its gene silencing technology is designed to regulate expression of various genes and the Company has its own delivery systems targeting a range of organs and cell types. Its RNA interference (RNAi) platform is known as AtuRNAi. The Company's delivery systems deliver both short interfering RNA (siRNA) and messenger RNA (mRNA). The Company has a genetic toolkit with its own therapeutic payloads to modulate gene expression up, as well as down in pre-clinical in vivo models.

Officers and directors

Ali Mortazavi Chief Executive Officer, Director
Timothy C. A. Freeborn Chief Financial Officer, Finance Director, Secretary, Director
Age: 54
Lars Karlsson Head of Research and Development, Executive Director
Age: 54
Michael Khan Ph.D. Chief Medical Officer, Director
Mark Cameron Head of Chemistry
Stephen B. Parker Independent Non-Executive Chairman of the Board
Age: 57
Stuart J.M. Collinson Ph.D. Non-Executive Director
Age: 54
Alistair William Gray Non-Executive Director
Age: 67